A STUDY TO EVALUATE THE EFFICACY OF VENETOCLAX IN RELAPSED/REFRACTORY PARTICIPANTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) INCLUDING THOSE WITH 17P DELETION OR TP53 MUTATION OR THOSE WHO HAVE RECEIVED A PRIOR B-CELL RECEPTOR INHIBITOR.: